Gland Pharma Limited's Q2 FY27 profit rises 58%

Gland Pharma Limited (NSE: GLAND) reported Q2 FY27 consolidated revenue of ₹1,834 crore, increasing 23.3% year-on-year. Net profit rose 58.3% to approximately ₹291 crore. The company's CDMO business recorded 31% year-on-year growth. EBITDA increased 39% to approximately ₹553 crore, indicating stronger operating performance compared with the same quarter last year. The profit growth is encouraging, but the sequential trend deserves attention. Net profit declined from approximately ₹317 crore in Q1 FY27 to ₹291 crore in Q2 FY27. This suggests that strong annual growth has not yet translated into continuous quarter-on-quarter improvement. In my view, the sustainability of CDMO growth and the company's ability to maintain operating margins will be important indicators. The next results should provide more clarity on business momentum and the contribution of new customer engagements. Analytical stance: Annual performance remains strong, but sequential profitability and CDMO growth need continued monitoring. GLAND